Observational studyOncoimmunology2025

Final 3-year results from the EVIDENS study, an observational study of nivolumab in non-small cell lung cancer.

Fabrice Barlesi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.